Cartherics, a Melbourne, Australia-based biotechnology company developing immune cell therapies for the treatment of cancer and other diseases, raised over $15M in funding.
Backers were not disclosed.
The company intends to use the funds for the clinical trial for CTH-401, its lead cell therapy for ovarian cancer, and expand its pipeline to include other diseases.
Led by CEO Prof. Alan Trounson AO, Cartherics is a biotechnology company developing cell-based immunotherapies for the treatment of cancer, with a portfolio of CAR-T and CAR-NK cell products. Its allogeneic cell platform is based upon iPSCs generated from donated cord blood that can be differentiated into NK cells, T cells and other immune system cells. The iPSCs are genetically engineered at specific “safe harbour” genomic sites to provide enhanced function for the derived NK and other immune cells.
The company’s lead CAR-NK cell product, CTH-401, carries a CAR directed against TAG-72, a well-validated tumour target, along with the deletion of two genes associated with immunosuppression.
FinSMEs
01/10/2024